Last week, Tai­wan-based CD­MO Bo­ra Phar­ma­ceu­ti­cals an­nounced that it ac­quired Eden Bi­o­log­ics. Now, it says that pur­chase has helped es­tab­lished Bo­ra Bi­o­log­ics, ex­pand­ing in­to the bio­phar­ma­ceu­ti­cal mar­ket.

The ac­qui­si­tion of the com­pa­ny’s as­sets, which are lo­cat­ed in the Hsinchu Bio­med­ical Sci­ence Park in Tai­wan, is help­ing Bo­ra build its pres­ence in the bio­phar­ma world by ex­pand­ing pro­duc­tion ca­pac­i­ty of cell lines for the pro­duc­tion of pro­tein drugs. It will al­so im­prove the qual­i­ty con­trol and in­spec­tion spec­i­fi­ca­tions, as well as cell bank gen­er­a­tion. The fa­cil­i­ty has four 500-liter biore­ac­tors that have been ap­proved by Eu­ro­pean and Tai­wanese reg­u­la­tors.

“The ad­di­tion of the CD­MO fa­cil­i­ties equip­ment and the ex­per­tise of the high­ly qual­i­fied team gives Bo­ra Bi­o­log­ics the abil­i­ty to de­vel­op and con­tin­ue with our clients as they progress to com­mer­cial­iza­tion,” Bo­ra VP Si­mon Chen said in a state­ment.

Taishin Health­care Part­ner­ship and Allen Chao, the founder of Tan­vex Bio­Phar­ma, are both in­vestors in Bo­ra Bi­o­log­ics.

On May 10, Evofem Bio­sciences an­nounced that it would en­list Bo­ra Cana­da to man­u­fac­ture Evofem’s drug Phexxi for mar­kets across the world. Evofem will get a 45% cut on the cost of goods, through send­ing man­u­fac­tur­ing, test­ing and pack­ag­ing to Bo­ra. Phexxi, a hor­mone-free con­tra­cep­tive, was ap­proved in 2020, and con­tin­ues to grow in pop­u­lar­i­ty for the use of pre­vent­ing preg­nan­cy in the US. The gel is used up to an hour be­fore sex. Its ad cam­paign fea­tures “Schitt’s Creek” star An­nie Mur­phy.

Earlier this year, Novartis touted its radioligand as a major piece to counter competition in the cancer space. However, the physical production of its products has had anything but a smooth ride.

In May, Novartis had to suspend production of Lutathera and Pluvicto, its two primary radiotherapies. According to the company, this was done out of an abundance of caution as a result of potential quality issues identified in its manufacturing. The production suspension impacts the commercial and clinical trial supply of the products.

Lonza has been expanding its reach across the globe, bringing sites in China and the US online this year, but now they are looking closer to home for their next major investment.

The Swiss manufacturer on Friday announced plans to construct a large-scale commercial drug fill and finish facility in the town of Stein, Switzerland. The new facility will be delivered through an investment of approximately CHF 500 million, or $519 million, and is expected to be completed in 2026. The facility will also be constructed on the same campus as Lonza’s current clinical drug product facility.

Two weeks ago, Biohaven hit an all-time high in weekly Nurtec prescriptions. CEO Vlad Coric attributes at least some of that success to a new interactive Twitter campaign that encourages patients to free their feed of potential migraine triggers.

Earlier this month, Biohaven in partnership with Twitter launched the #RelieveYourFeed campaign that allows users to customize their app settings based on their migraine triggers.

Over the past few months, oncologists have been talking a lot about the ASCO conference. Not surprising considering its import and the study data presented, but what may be less expected is the second most talked about topic of health equity.

That’s according to data from The Harris Poll and the new expert network the researcher is building out. While the company has been doing deep data dives into specific health issues or conditions for pharma clients, it’s now monitoring influencer networks of therapy area specialists to find out what experts are really thinking about.